Australia on Friday reported its first death from blood clots in the recipient of the AstraZeneca COVID-19 rifle, with its regulator saying there may be a link between the death of a 48-year-old woman and a vaccine.
His was the third case of rare blood stains from people who had been vaccinated in Australia. The other two are still recovering well, added Trapeutic Thers Management (TGA).
It said it was “carefully reviewing” similar conditions in Australia.
A New South Wales woman received the AstraZeneca vaccine on April 8, the day the government announced that the Pfizer vaccine would be given as preferred to patients under the age of 50, delaying its roll-out program.
If there was no other reason for the ice to be created, Australia’s Vaccine Safety Investigation Group (VSIG) “believed the link to the vaccine should be taken at this time,” the TGA said.
VSIG held a meeting on Friday following the news of the woman’s death.
The TGA said his case was complicated by medical conditions, including diabetes, “and other abnormalities.”
There have been at least 885,000 doses of AstraZeneca vaccine given in Australia to date, equivalent to the frequency of blood transfusions in all 295,000 cases, the TGA said.
“The total number … so far has never exceeded the expected origin level for the most common type of blood clots,” it said.
The UK regulator, the Medicine and Healthcare Products Regulatory Agency, has concluded by reviewing reported cases in the UK that the highest risk for cerebral venous sinus thrombosis – a rare blood clot in the brain – was about 1 in 250,000 who received the vaccine.
Australia has reported more than 22,000 cases of COVID-19 public transmission and 909 deaths.